Glaxo SmithKline
This article was originally published in The Tan Sheet
Executive Summary
John Ziegler will assume the position of president, Consumer Healthcare, the same position he currently holds for SmithKline Beecham, and will report to Glaxo SmithKline CEO-designate Jean-Pierre Garnier under a corporate executive structure for the newly proposed merged entity announced Feb. 3. The heads of the firm's U.S. pharmaceutical operations will be George Morrow and David Stout, who hold the same positions at Glaxo Wellcome and SmithKline, respectively. They will report to Robert Ingram, who will take over as chief operating officer and president of Pharmaceutical Operations worldwide. The three could play a prominent role in determining a switch strategy; in announcing the proposed merger, company execs noted the switch potential of several Rx drugs, such as Relenza influenza treatment, Lotronex for irritable bowel syndrome and Flonase for allergic rhinitis (1"The Tan Sheet" Jan. 24, p. 3)
You may also be interested in...
Glaxo SmithKline OTC Switch Potential Seen As Merger Catalyst
The Rx influenza treatment Relenza tops the list of potential OTC switch candidates in the Glaxo SmithKline portfolio, according to merger details announced the week of Jan. 17.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands